Bonum Therapeutics’ Post

Join Diane Ramsden, PhD, from AstraZeneca, and Lindsey Whaley, MS, from LifeNet Health, for an inside look at TruVivo™, a novel all-human in vitro hepatocyte system developed by LifeNet Health LifeSciences. Current in vitro hepatic models, such as sandwich cultures, lose key hepatocellular function and enzymatic activity over time. More advanced co-culture platforms have been introduced but are often complex or contain non-human cells that can alter results due to innate background contribution to metabolism. These limitations make it challenging to characterize human mechanisms for the metabolism of drug candidates, especially those that are slowly metabolized. To address these limitations, TruVivo was developed as the first and only 2D+ hepatic system to provide human-relevant, reliable results in an easy-to-use format. In this webinar, Lindsey Whaley will introduce key features of the TruVivo™ system that demonstrate its potential to be an ideal platform for drug discovery and development applications. Diane Ramsden will then present data from her evaluation of TruVivo™ as a potential tool for investigating mechanistic drug metabolism and pharmacokinetics, including drug-drug interaction potential, and translational risk assessment. #dmpk #drugdevelopment #drugsafety #drugdiscovery

I feel on cloud nine to announce the publication of our article entitled “Selective Inhibition of indoleamine and tryptophan 2,3-dioxygenases: Comparative Study on Kynurenine Pathway in Cell Lines via LC-MS/MS-based Targeted Metabolomics” available under open access licence for everyone who may be interested in. 😄 Here you may find the direct link: https://lnkd.in/gyutZR78 It concerns a validated LC-MS/MS method to quantify the “kynurenines”, which are the major tryptophan catabolites, in cellular supernatants. Our method was successfully applied to assess the in vitro potency of IDO1 selective inhibitors in early drug discovery phases and to obtain vital information about our cell models (A375, U87, MDA-MB-231 cell lines). All the obtained info will be exploited to support the biological characterization of novel inhibitors targetting IDO or TDO. Hence, it is not the end of our journey definetely. 🔬 #LCMS #KynureninePathway #IDO #TDO #TargetedMetabolomics Undoubtedly the support and collaboration provided by Professors Silvia Fallarini, Silvio Aprile, and Tracey Pirali were crucial for the success of this paper, thank you very much. 🤝 I leap at the occasion to sincerely thank Sarah Jane Rezzi, and Rita Maria Concetta Di Martino for the active collaboration and support, I appreciated it heartly. 😊 Last but not the least, I give my heartfelt acknowledgements to Professor Erika Del Grosso for her fundamental guidance without which it couldn’t be possible. 🤗 I know this is just the beginning of my journey as a scientist, but I will never give up; looking straight forward for the self-improvement. Thank you to everyone who has been or will be part of this journey! 🤞

One of the most important aspects of this is the up-and-coming platform to deal with patients with thyroid disease. As Cynthia and I discussed in our recent interview (see https://lnkd.in/ezdTkQAW) it could actually supplant T1D near-term as Sernova's most important and monetarily lucrative application.

The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal... READ ARTICLE FOLLOW #ProducedbyANP 🎬 #ANPharmaUpdate #Pharmanews #pharmamarketing #pharmamarketingnews

Last week, our R+D Team Lead, Stuart Prime, delivered a talk that got ALS researchers very excited! Stuart spoke at the 2nd ALS Drug Development Summit 2023, a place for discussion and innovation directed towards new therapies for ALS, the incurable motor neuron disease. Stuart presented data on our work using human iPSC-derived cells to build complex in vitro NMJ models for research and drug discovery. From the rapid 10-day maturation times, using our Maturation Accelerator, to the hyperexcitability MEA data, it's impressive work. So we've written a short article explaining where this research is going, and how it fits into our work with ALS disease models. Read it here: https://hubs.la/Q01Rkg620 #ALS #biopharma #ipscs #BetterHumanDiseaseModels #drugdevelopment

We're proud to support Oxford Global at #RNA Therapeutics & Delivery Europe. Our keynote is titled "Drug and target discovery with explainable AI" -- don't miss it! #drugdiscovery #explaianbleai #scientificAI #pharma #rnatherapeutics

Introducing Our Latest Expansion in Biomarker Analysis: Gyrolab® Mouse Cytokine Kits! 🐭 Fast and accurate measurement of 5 murine inflammatory cytokines: IL-4, IL-6, IL-10, IFN-gamma, and TNF-alpha   By requiring small sample volumes, these ready-to-use kits optimize the amount of information achieved from each mouse sample.   The Gyrolab Mouse Cytokine Kits have everything you need to run these assays using the Gyrolab Bioaffy™ 4000 CD, generating 96 datapoints with minimal hands-on time. Providing high sensitivity and robust assay performance, these kits are validated to achieve excellent specificity, dilution linearity, parallelism, and spike recovery. These Gyrolab Mouse Cytokine kits support biomarker studies in drug development programs from discovery to pre-clinical studies. https://lnkd.in/d67gwFjX   #biomarkers #biomarker #immunoassay #drugdevelopment

Yesteday we presented data from preclinical studies of Auxora in acute kidney injury at the 29th International AKI & CRRT Conference. The data show that Auxora hastens recovery of kidney function and improves survival in a rat model of #AKI. https://lnkd.in/g5h4vxbY